Eris Lifesciences acquires 30 Percent stake in Swiss Parenterals through share swap
Eris Lifesciences agreed to acquire a 30% stake in Swiss Parenterals for ₹423.3 crore via a share swap transaction. The move strengthens strategic control and prepares the platform for full ownership. The acquisition is expected to support scale, cost efficiency, and financial consolidation once regulatory clearances are completed.
By Finblage Editorial Desk
5:30 pm
25 November 2025
Sources & Disclaimer
This article is compiled from publicly available information, including company disclosures, stock exchange filings, regulatory announcements, and reports from global and domestic financial publications. The content has been editorially reviewed and enhanced by the Finblage Editorial Desk for clarity and investor awareness purposes only.
All information provided on Finblage is strictly for educational and informational use and should not be considered as financial, investment, legal, or professional advice. Readers are advised to conduct their own independent research and consult a certified financial advisor before making any investment decisions. Finblage shall not be held responsible for any losses arising from the use of information published on this website.
_edited.png)





